Business Wire

Tanium Converge Travels to London and Paris

13.4.2023 10:00:00 EEST | Business Wire | Press release

Share

Tanium, the industry’s only provider of converged endpoint management (XEM), today announced the beginning of the Converge World Tour 2023, a six-city series of its global user conference. The kickoff event in London will be held Tuesday, 18th April, at the London Landmark Hotel, with a show at the Campus Cyber, Paris to follow on Thursday where Tanium will showcase its innovation spotlight, including its product roadmap and future enhancements to the XEM platform.

Converge is Tanium’s flagship event that brings together industry specialists, peers, and partners to share strategies for leveraging converged endpoint management (XEM) to improve organizational cybersecurity readiness and response. There’s no better opportunity for IT and security practitioners to discover new ways of driving value to their boards and accelerating business initiatives than to gain outside perspectives and hear first-hand experiences from those on the frontline of the cyber landscape.

“Tanium’s commitment is first, last, and always to our customers, and we are grateful to have such a strong and extensive partner ecosystem that is equally committed to maximizing the value our customers achieve from their investments in Tanium,” said Steve Daheb, chief marketing officer at Tanium. “Join us in Paris and London to see why Forrester reports Tanium driving ROI of more than 200% for customers, why eight of top 10 global financial institutions and seven of the top 10 global retailers trust Tanium to maximize their ROI and simplify their technology environments while defending their organizations against emerging threats and expanding their knowledge of managing risk, securing technology, and unlocking innovation at scale from a single intuitive platform.”

Join Tanium for a dynamic keynote experience, featuring top executives and industry experts who will enable you to:

  • Glimpse into the future with Tanium—including the global unveiling of a new offering designed to improve overall work productivity, increase employee satisfaction, and lower IT support costs
  • Understand the use and benefits of XEM with category creator Steve Daheb
  • Gain insights from an intimate fireside chat with customer success champion Charles Ross
  • Explore the many ways Microsoft and Tanium work better together to improve cyber resilience with partner facilitator Mike Fiorina
  • Get a firsthand look at real customer successes with a panel featuring Aviva and Fraser’s Group and partner enablement executive Todd Palmer
  • Participate in peer-based breakout sessions across executive-, technical-, and partner-focused tracks

WHO : IT and security professionals from across Europe; Tanium’s newly appointed CEO, Dan Streetman, and members of his executive team; Forrester analyst Andrew Hewitt; Frasers Group’s Matthew Wilmot; Aviva’s Marc Hasketh-Boston; and Tanium customers and partners that include EY, PwC, Armadillo Managed Services, Computacenter, SCC, EndpointX, Pointwire, BlueTrusty, Capgemini, Cegedim, DOUNYX, EY, I-TRACING, Orange Cyberdefense, and more

WHAT : Tanium Converge London and Tanium Converge Paris, featuring spotlights on current trends, industry best practices, expert-led sessions, breakout discussions, and hands-on labs

WHER E: The Landmark London Hotel and the Campus Cyber in Paris–La Defense

WHEN : Tuesday, 18th April 2023 (London) and Thursday, 20th April (Paris)

HOW : The shows are sold out, but you can still register to secure your place on the waitlist or join us for mainstage public sessions on demand by signing up for the London show or the Paris event. We look forward to seeing you there!

About Tanium

Tanium, the industry’s only provider of converged endpoint management (XEM), is the reference platform of choice to manage complex security and technology environments. Only Tanium unifies teams and workflows and protects every endpoint from cyber threats by integrating IT, Compliance, Security, and Risk into a single platform that delivers comprehensive visibility across devices, a unified set of controls, and a common taxonomy for a single shared purpose: to protect critical information and infrastructure at scale. Tanium has been named to the Forbes Cloud 100 list for seven consecutive years and ranks on Fortune’s list of the Best Large Workplaces in Technology. In fact, more than half of the Fortune 100 and the U.S. armed forces trust Tanium to protect people; defend data; secure systems; and see and control every endpoint, team, and workflow everywhere. That’s the power of certainty. Visit www.tanium.com and follow us on LinkedIn and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lindsey Lockhart
Tanium PR
press@tanium.com
+ 1 214.562.1521

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye